Atlas Trials

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Clinical trial NCT05384119 · TERMINATED

Trial details

NCT number
NCT05384119
Sponsor
Tvardi Therapeutics, Incorporated
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Breast Cancer
Start date
2023-01-09
Primary completion
2024-04-25
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.